Daily startup and blockchain data-wiki with interviews, Q&A's & discussions about funding rounds & investors.

RaisedToday moderators manually update and approve wiki edits - check back every 1-2h for approved submissions.

Contributed by laura998

Entrada Therapeutics

3 Disclosed Funding Rounds $59,599,999

0 Participating Investments


Emergency Medicine, Health Care, Genetics, Biotechnology, Medical

Entrada Therapeutics is a developer of novel therapeutics intended to treat devastating diseases.

Boston, Massachusetts, United States, North America (US)

Organizations in Boston in Emergency Medicine,
Organizations in Boston in Health Care,
Organizations in Boston in Genetics,
Organizations in Boston in Biotechnology,
Organizations in Boston in Medical,
Organizations in Massachusetts in Emergency Medicine,
Organizations in Massachusetts in Health Care,
Organizations in Massachusetts in Genetics,
Organizations in Massachusetts in Biotechnology,
Organizations in Massachusetts in Medical,
Organizations in United States in Emergency Medicine,
Organizations in United States in Health Care,
Organizations in United States in Genetics,
Organizations in United States in Biotechnology,
Organizations in United States in Medical,
Organizations in North America in Emergency Medicine,
Organizations in North America in Health Care,
Organizations in North America in Genetics,
Organizations in North America in Biotechnology,
Organizations in North America in Medical

Investors in Boston in Emergency Medicine,
Investors in Boston in Health Care,
Investors in Boston in Genetics,
Investors in Boston in Biotechnology,
Investors in Boston in Medical,
Investors in Massachusetts in Emergency Medicine,
Investors in Massachusetts in Health Care,
Investors in Massachusetts in Genetics,
Investors in Massachusetts in Biotechnology,
Investors in Massachusetts in Medical,
Investors in United States in Emergency Medicine,
Investors in United States in Health Care,
Investors in United States in Genetics,
Investors in United States in Biotechnology,
Investors in United States in Medical,
Investors in North America in Emergency Medicine,
Investors in North America in Health Care,
Investors in North America in Genetics,
Investors in North America in Biotechnology,
Investors in North America in Medical

Greater Boston Area (0 Investors) (0 Startups), New England (0 Investors) (0 Startups), East Coast (0 Investors) (0 Startups), Northeastern US (0 Investors) (0 Startups)

Founded date 01, 2016

Founders Leo Qian, Dehua Pei

Operating Status Active

Funding Stage Early Stage Venture

Last Funding Type Series A

Also known as Entrada

Company Type For Profit


LinkedIN Link

Wikipedia Link

Entrada Therapeutics’ mission is to treat devastating diseases through the intracellular delivery of biologics. Entrada’s technology enables the efficient intracellular delivery of proteins, peptides and nucleic acids, thus allowing for the development of programs across several intracellular target classes. The Company's novel approach addresses current challenges associated with both large and small molecule therapeutics and represents a fundamental advancement in the delivery of molecules into the cytosol. For more information, please visit www.entradatx.com.

Date Round Raised Lead
March, 31, 2021 Series B $116,000,000 Wellington Management
December, 18, 2018 Series A $59,000,000 MPM Capital, 5AM Ventures
October, 27, 2016 Seed $599,999 -------

Entrada Therapeutics Investors (19)

Investor Lead? Round Participating Raise Date Partners
TCG Crossover No Series B $116,000,000 March, 31, 2021 -------
Wellington Management Yes Series B $116,000,000 March, 31, 2021 -------
Roche Venture Fund No Series B $116,000,000 March, 31, 2021 -------
Redmile Group No Series B $116,000,000 March, 31, 2021 -------
Qatar Investment Authority No Series B $116,000,000 March, 31, 2021 -------
Point72 Ventures No Series B $116,000,000 March, 31, 2021 -------
MRL Ventures Fund No Series B $116,000,000 March, 31, 2021 -------
MPM Capital No Series B $116,000,000 March, 31, 2021 -------
Moore Strategic Ventures No Series B $116,000,000 March, 31, 2021 -------
Greenspring Associates No Series B $116,000,000 March, 31, 2021 -------
Goldman Sachs No Series B $116,000,000 March, 31, 2021 -------
Agent Capital No Series B $116,000,000 March, 31, 2021 -------
5AM Ventures No Series B $116,000,000 March, 31, 2021 -------
CureDuchenne Ventures No Series B $116,000,000 March, 31, 2021 -------
Agent Capital No Series A $59,000,000 December, 18, 2018 -------
Roche Venture Fund No Series A $59,000,000 December, 18, 2018 -------
MRL Ventures Fund No Series A $59,000,000 December, 18, 2018 -------
MPM Capital Yes Series A $59,000,000 December, 18, 2018 -------
5AM Ventures Yes Series A $59,000,000 December, 18, 2018 -------